eXoZymes, Inc. (EXOZ) 10-Year Financial Performance & Capital Metrics

EXOZ • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AbouteXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.Show more

Revenue $0
EBITDA -$6M -254.2%
Net Income -$6M -187.5%
EPS (Diluted) -0.72 -188.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -116.8% +71.7%
ROIC -273.85% -162.6%
Debt/Equity 0.13
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-62.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM-93.65%

ROCE

10Y Avg-84.49%

5Y Avg-84.49%

3Y Avg-90.51%

Latest-92.37%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	59.41K	147.75K	0	267.38K
COGS % of Revenue	-	-	-	-
Gross Profit+	-59.41K	-147.75K	0	-267.38K
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-1.49%	1%	-
Operating Expenses+	1.23M	1.18M	1.8M	5.66M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	778.99K	836.83K	1.34M	3.8M
SG&A % of Revenue	-	-	-	-
Research & Development	454.45K	348.08K	527.48K	1.87M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	-70.07K	0
Operating Income+	-1.29M	-1.33M	-1.8M	-5.93M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-0.03%	-0.35%	-2.3%
EBITDA+	-1.23M	-1.18M	-1.6M	-5.66M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	0.04%	-0.35%	-2.54%
D&A (Non-Cash Add-back)	59.41K	147.75K	196.94K	267.38K
EBIT	-1.21M	-1.33M	-1.8M	-5.86M
Net Interest Income+	0	98	100	77.61K
Interest Income	0	98	100	77.61K
Interest Expense	0	0	0	0
Other Income/Expense	83.74K	98	-199.9K	70.77K
Pretax Income+	-1.21M	-1.33M	-2M	-5.86M
Pretax Margin %	-	-	-	-
Income Tax+	0	63.56K	42.27K	0
Effective Tax Rate %	1%	1.05%	1.02%	1%
Net Income+	-1.21M	-1.4M	-2.04M	-5.86M
Net Margin %	-	-	-	-
Net Income Growth %	-	-0.15%	-0.46%	-1.88%
Net Income (Continuing)	-1.21M	-1.4M	-2.04M	-5.86M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.15	-0.17	-0.25	-0.72
EPS Growth %	-	-0.13%	-0.47%	-1.88%
EPS (Basic)	-0.15	-0.17	-0.25	-0.72
Diluted Shares Outstanding	8.13M	8.13M	8.13M	8.13M
Basic Shares Outstanding	8.13M	8.13M	8.13M	8.13M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.05M	1.47M	1.21M	10.82M
Cash & Short-Term Investments	547.81K	558.57K	66.53K	9.72M
Cash Only	547.81K	558.57K	66.53K	9.72M
Short-Term Investments	0	0	0	0
Accounts Receivable	468.35K	809.53K	882.32K	737.28K
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	30.19K	101.14K	264.76K	363.79K
Total Non-Current Assets+	1.3M	1.22M	2.34M	2.21M
Property, Plant & Equipment	1.3M	1.22M	2.34M	2.21M
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	2.35M	2.69M	3.56M	13.03M
Asset Turnover	-	-	-	-
Asset Growth %	-	0.14%	0.33%	2.66%
Total Current Liabilities+	400.78K	634.36K	2.42M	1.33M
Accounts Payable	267.3K	385.8K	702.91K	924.25K
Days Payables Outstanding	1.64K	953.06	-	1.26K
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	1M	0
Current Ratio	2.61x	2.32x	0.50x	8.12x
Quick Ratio	2.61x	2.32x	0.50x	8.12x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	748.25K	678.77K	1.53M	1.28M
Long-Term Debt	0	0	0	0
Capital Lease Obligations	587.14K	463.77K	1.39M	1.16M
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	123.58K
Total Liabilities	1.15M	1.31M	3.94M	2.61M
Total Debt+	720.63K	608.77K	1.61M	1.39M
Net Debt	172.82K	50.2K	1.55M	-8.33M
Debt / Equity	0.60x	0.44x	-	0.13x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-	-
Total Equity+	1.2M	1.37M	-384.32K	10.42M
Equity Growth %	-	0.15%	-1.28%	28.11%
Book Value per Share	0.15	0.17	-0.05	1.28
Total Shareholders' Equity	1.2M	1.37M	-384.32K	10.42M
Common Stock	12	6	6	8
Retained Earnings	-2.65M	-4.05M	-6.08M	-11.95M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.59M	-1.26M	-1.18M	-8.51M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	0.21%	0.06%	-6.2%
Net Income	-1.21M	-1.4M	-2.04M	-5.86M
Depreciation & Amortization	59.41K	147.75K	196.94K	267.38K
Stock-Based Compensation	198.46K	216.5K	281.54K	1.13M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	-99K	-35.15K	158.73K	-19.4K
Working Capital Changes	-536.48K	-190.07K	220.31K	-4.02M
Change in Receivables	-317.07K	-341.18K	-72.79K	145.04K
Change in Inventory	0	0	0	0
Change in Payables	-214.43K	118.5K	272.89K	221.34K
Cash from Investing+	-312.25K	-87.21K	-311.17K	-359.22K
Capital Expenditures	-422.59K	-185.98K	-288.71K	-396.45K
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	110.33K	98.77K	-22.45K	37.23K
Cash from Financing+	2.31M	1.36M	1M	18.52M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	1M	11.82K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-2.01M	-1.44M	-1.47M	-8.9M
FCF Margin %	-	-	-	-
FCF Growth %	-	0.28%	-0.02%	-5.06%
FCF per Share	-0.25	-0.18	-0.18	-1.10
FCF Conversion (FCF/Net Income)	1.31x	0.90x	0.58x	1.45x
Interest Paid	0	0	0	0
Taxes Paid	0	0	63.56K	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-101%	-108.66%	-412.54%	-116.8%
Return on Invested Capital (ROIC)	-	-71.58%	-104.28%	-273.85%
Debt / Equity	0.60x	0.44x	-	0.13x
FCF Conversion	1.31x	0.90x	0.58x	1.45x

Frequently Asked Questions

Growth & Financials

eXoZymes, Inc. (EXOZ) grew revenue by 0.0% over the past year. Growth has been modest.

eXoZymes, Inc. (EXOZ) reported a net loss of $8.3M for fiscal year 2024.

Dividend & Returns

eXoZymes, Inc. (EXOZ) has a return on equity (ROE) of -116.8%. Negative ROE indicates the company is unprofitable.

eXoZymes, Inc. (EXOZ) had negative free cash flow of $10.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener